Becton, Dickinson and Company
One Becton Drive
Franklin Lakes
New Jersey
07417
United States
Tel: 201-847-6800
Fax: 201-847-6475
Website: http://www.bd.com/
866 articles about Becton, Dickinson and Company
-
BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency
11/30/2023
BD, a leading global medical technology company, launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters, central venous catheters, IV lines and other vascular access devices.
-
FDA Safety Communication Does Not Impact BD Syringes
11/30/2023
BD, a leading global medical technology company, issued the following statement regarding the U.S. Food and Drug Administration Safety Communication on evaluation of certain plastic syringes:.
-
BD Names Dr. Ronald Silverman as Chief Medical Officer
11/21/2023
BD, a leading global medical technology company, announced that Ronald Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.
-
BD to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/14/2023
BD, a leading global medical technology company, announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 8:20 am Eastern Time.
-
BD Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
11/9/2023
BD, a leading global medical technology company, announced results for its fourth quarter and full year of fiscal 2023, which ended September 30, 2023.
-
BD Board Increases Dividend for 52nd Consecutive Year
11/9/2023
The Board of Directors of BD has declared a quarterly dividend of $0.95 per common share, an increase of 4.4% from the previous quarter.
-
BD Advances "One-Stick Hospital Stay" Vision with Launch of Next-Generation Needle-Free Blood Draw Technology
11/2/2023
BD, a leading global medical technology company, launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay."
-
BD Names Greg Rodetis as Senior Vice President of Investor Relations
10/17/2023
BD, a leading global medical technology company, announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.
-
BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices
10/16/2023
BD announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.
-
BD to Announce Fiscal 2023 Fourth Quarter and Full Year Financial Results
10/12/2023
BD, a leading global medical technology company, announced that it will report its fiscal 2023 fourth quarter and full year financial results on Thursday, November 9, 2023.
-
BD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards
9/19/2023
BD announced it has been ranked in the top 10 for overall transparency and awarded Best Code of Conduct among S&P 250 companies in the fifth annual U.S. Transparency Awards by Labrador, a global communications firm specializing in corporate disclosures.
-
Navigate BioPharma Services, Inc. Announces Collaboration with BD (Becton, Dickinson and Company) to Advance Capabilities for Clinical Phases of Drug Development
9/7/2023
Navigate BioPharma Services, Inc. announces a strategic collaboration with BD (Becton, Dickinson and Company) to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.
-
BD to Present at Investor Healthcare Conferences - August 23, 2023
8/23/2023
BD, a leading global medical technology company, announced that it will present at the following healthcare conferences.
-
BD Reports Third Quarter Fiscal 2023 Financial Results
8/3/2023
BD, a leading global medical technology company, announced results for its third quarter of fiscal 2023, which ended June 30, 2023.
-
STERIS Completes the Acquisition of Surgical Instrumentation Assets from BD
8/2/2023
STERIS plc announced that it has completed the previously announced acquisition of the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from BD .
-
BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test
8/1/2023
BD, a leading global medical technology company, announced U.S. Food and Drug Administration 510 clearance for the BD Respiratory Viral Panel for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus in approximately two hours.
-
BD Board Declares Dividend - July 25, 2023
7/25/2023
The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, payable on September 29, 2023 to holders of record on September 8, 2023.
-
BD CEO Tom Polen Addresses FDA 510(k) Clearance of BD Alaris™ Infusion System
7/24/2023
BD Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration 510 clearance for the updated BD Alaris™ Infusion System:.
-
BD Names Joanne Waldstreicher to Board of Directors
7/24/2023
BD, a leading global medical technology company, announced the appointment of Dr. Joanne Waldstreicher to its board of directors.
-
BD Issues FY 2022 ESG Report, Highlights Notable Progress in Energy and Waste Reduction, Health Care Access and Diversity
7/20/2023
BD, a leading global medical technology company, issued its Fiscal Year 2022 Environmental, Social and Governance Report that details ongoing efforts that impact company health, human health, community health and planet health.